REHOVOT, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) ( http://www.Todosmedical.com ) today announced that its Board of Directors has appointed Herman Weiss, MD MBA as the new Chief Executive Officer of the company, effective July 30, 2018. Concurrently with Dr. Weiss’ appointment as Chief Executive Officer, Dr. Weiss stepped down as the Chairman of the Board of Directors.

“I am honored to have been appointed as the next CEO of Todos Medical, Ltd. It is a privilege to be part of an organization that is striving to develop and bring to market simple blood tests for early cancer detection,” said Dr. Weiss. “We are a medical diagnostic company that is led by a purpose - to save lives through early cancer detection while being minimally invasive to the patient.”

Dr. Weiss succeeds Rami Zigdon, MBA, who will now hold the position of Chief Business Officer. Additionally, Mr. Zigdon will remain on the Board of Directors of the company.

Procedurally, Dr. Weiss immediately vacated his position as Chairman of the Board of Directors, although the company intends to re-appoint Dr. Weiss as Chairman of the Board of Directors, subject to approval by the company’s shareholders.

From March 2016 to June 2018, Dr. Weiss, served as Vice President of Medical Affairs and Clinical Development for Juniper Pharmaceuticals Inc. and from December 2010 to March 2016, he served as the Global Medical Director of Women’s Health and Bone Health at Teva Pharmaceutical Industries, Ltd. Dr. Weiss received an MBA from the George Washington University, Washington DC, an M.D. from the Ohio State University College of Medicine Columbus, OH and a B.A. in Philosophy (Summa Cum Laude) from Ramapo College of New Jersey. Dr. Weiss has served as a consultant to multiple medical device and pharmaceutical companies including American Medical Systems and venture capital firms in NYC and also founded and served as the CMO of a biotech medical device company in Israel. He owns multiple patents and is the author of numerous publications in the area of women’s health/gynecology.

About Todos Medical

Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on Todos Biochemical Infrared Analyses (“TBIA”), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU. For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expectation to appoint Dr. Weiss as Chairman of the Board of Directors, subject to shareholder approval, and our expected clinical development programs and clinical trials. These forward-looking statements are only based on the current expectations of the management of Todos Medical, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the company is contained under the heading “risk Factors” in Todos Medical, reference is made to Todos Medical Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (“SEC”) which is available on the SEC's website, www.sec.gov. and in the Company’s period filings with the SEC.

Media Contact:

Todos Medical Ltd.Daniel HirschInvestor Relations Dan.h@todosmedical.com (347) 699-0029